ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock opened at $24.79 in last session, and closed at $28.84, while the day range of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock is $24.60 – $29.50. The stock showed a positive weekly performance of 17.67%.
XOMA Corp. (NASDAQ:XOMA) CEO John Varian sold 10,000 shares of XOMA Corp. stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $7.55, for a total value of $75,500.00. XOMA Corp (NASDAQ:XOMA) stock opened at $7.64 in last session, and closed at $8.48 by gaining 11.58%. The 52 week range of $2.46 – $8.99. Company’s market capitalization is $738.04M.
Celldex Therapeutics, Inc. (NASDAQ:CLDX), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock increased 9.74% and finished the last session at $31.56. The EPS of the stock remained -1.02. Company’s market capitalization is $2.56B.
Agenus Inc. (NASDAQ:AGEN) on Feb. 13 said it has completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company. The acquisition includes the Retrocyte Display® technology platform which enables rapid discovery and optimization of fully human antibodies against a wide array of molecular targets. Agenus Inc. (NASDAQ:AGEN) stock opened the session at $3.72, and closed the session at $3.88. The 52 week range of the Agenus Inc. (NASDAQ:AGEN) stock remained $2.40 – $5.40 and the day range was $3.60 -$4.04.
Leave a Reply